Islets co-engineered with thrombomodulin and CD47 achieve sustained survival in allogeneic recipients without chronic immunosuppression
JCI Insight · 2026
DOI: 10.1172/jci.insight.200686 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCI Insight, 2026. Verfasst von Shadab Kazmi und 8 weiteren Autor:innen. Hauptthemen laut MEDLINE: Thrombomodulin, Islets of Langerhans Transplantation, CD47 Antigen, Islets of Langerhans. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: NIH.
Abstract (Originalsprache)
Allogeneic islet transplantation is an effective treatment for type 1 diabetes, but its clinical use is limited by rejection involving innate and adaptive immune responses, requiring lifelong immunosuppression. We herein engineered islets that transiently display 2 immunomodulators chimeric with streptavidin (SA), thrombomodulin (SA-TM) and CD47 (SA-CD47), for localized modulation of both innate and adaptive immune responses. The engineering process did not impact islet viability, glucose responsiveness, and metabolic activity. Intraportal transplantation into allogeneic recipients achieved sustained survival, with 8 out of 11 grafts surviving 120–330 days without immunosuppression. In contrast, non-engineered islets were acutely rejected (median survival time [MST] = 12 days), while islets engineered with SA-TM showed delayed rejection (MST = 13.5 days) and those with SA-CD47 exhibited prolonged survival (MST = 24 days). Double-engineered islets generated a localized tolerogenic immune environment characterized by low frequencies of inflammatory innate immune cells and increased frequencies of M2 macrophages, myeloid-derived suppressor cells, and CD4 + FoxP3 + T regulatory cells. The transcriptomic analysis showed downregulation of proinflammatory and upregulation of immune regulatory pathways. Our results demonstrate that transient co-display of immunomodulatory molecules on the islet surface is a versatile platform with significant translational potential for islet transplantation. Engineering transplanted islets with thrombomodulin and CD47 protects them from immune attack, enabling long-term survival in diabetic recipients without the need for chronic immunosuppressive drugs.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Förderung
- NIH
Zitieren
APA
Kazmi, S., Tarique, M., Badal, D., Ulker, V., Turan, A., Yee-Flores, K. M., Jadou Nejma, A., Yolcu, E. S., & Shirwan, H. (2026). Islets co-engineered with thrombomodulin and CD47 achieve sustained survival in allogeneic recipients without chronic immunosuppression. JCI Insight. https://doi.org/10.1172/jci.insight.200686
Vancouver
Kazmi S, Tarique M, Badal D, Ulker V, Turan A, Yee-Flores KM, et al. Islets co-engineered with thrombomodulin and CD47 achieve sustained survival in allogeneic recipients without chronic immunosuppression. JCI Insight. 2026. doi:10.1172/jci.insight.200686
BibTeX
@article{Kazmi2026,
author = {Kazmi, Shadab and Tarique, Mohammad and Badal, Darshan and Ulker, Vahap and Turan, Ali and Yee-Flores, Kathleen M and Jadou Nejma, Abdalmonam and Yolcu, Esma S and Shirwan, Haval},
title = {Islets co-engineered with thrombomodulin and CD47 achieve sustained survival in allogeneic recipients without chronic immunosuppression},
journal = {JCI Insight},
year = {2026},
doi = {10.1172/jci.insight.200686}
}
EUVIMED